Dechra Pharmaceuticals PLC/Osurnia business of Elanco Animal Health Incorporated Merger Inquiry

The CMA is investigating the anticipated acquisition by Dechra Pharmaceuticals PLC of the Osurnia business of Elanco Animal Health Incorporated.

Statutory timetable

Phase 1 date Action
TBC Deadline for phase 1 decision (*)
TBC Launch of merger inquiry
26 March 2020 to 17 April 2020 Invitation to comment

*This date is the current statutory deadline by when the decision will be announced. If any change occurs, the information is refreshed as soon as practicable. However, the CMA cannot guarantee that the decision will be announced on or before this current deadline, as the deadline of a given case may change during the merger assessment process due to different reasons.

The CMA has decided to investigate this transaction and is inviting comments. This case page will be updated when the CMA formally commences its phase 1 investigation.

Phase 1

Invitation to comment: Closes on 17 April 2020

26 March 2020: The CMA is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.


Please send written representations about any competition or public interest to:

James McGarrachan

Please note that, due to the ongoing COVID-19 outbreak, the CMA’s offices across the UK are closed until further notice. We are no longer able to accept delivery of any documents or correspondence by post or courier to any of our offices.

Published 26 March 2020